CO2 LADD TAC With and Without 5-FU for Hypertrophic Burn Scars: A Triple-Blinded, Split Scar RCT

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-89
SponsorUniversity of California, Davis

About this trial

Burn scars can sometimes heal in a way that causes them to become thick, raised, and stiff. These scars may itch, feel uncomfortable, limit movement, and affect how the skin looks. Because of this, many burn survivors look for treatments that can help improve both the appearance and the symptoms of their scars.

One treatment that has shown promise is fractional CO₂ laser therapy. This laser creates tiny openings in the scar tissue that help soften the scar and stimulate the skin to remodel itself. These openings can also help medications applied to the skin reach deeper into the scar where they may work better.

A steroid medication called triamcinolone is commonly used to treat these scars. Another medication, called 5-fluorouracil (5-FU), has been shown in prior studies to work well when combined with steroids, but it is usually given by injection, which can be painful and sometimes causes side effects.

In this study, we will look at whether delivering these medications through the laser openings can improve scars more effectively. Each participant's scar will be divided into two halves. One side will receive both medications, and the other side will receive the steroid alone. By comparing the two sides of the same scar, we hope to better understand whether adding 5-FU provides additional benefit.

Eligibility criteria

Qualifiers

Patient with hypertrophic scarring secondary to burn injury

Ages 18-89

Disqualifiers

Pregnant patients or patients of childbearing age, sexually active, and unwilling to utilize contraception

Children

Individuals that are cognitively impaired and unable to provide consent

Currently breastfeeding

Trial design

Treatments tested in this trial

  • Fractional Ablative CO₂ Laser
  • Triamcinolone Acetonide
  • Fluorouracil (5-FU)

Treatment groups

65 Participants
are divided into 2 treatment groups

Locations

This trial has no locations